Our medical correspondent Dr. Jon LaPook reported on how doctors are using biological treatments to speed athletes' recovery times. Now he's filling in more details on how such treatments work. — and how they might be approaching a tipping point.
PRP therapy is already being used in Europe. In the United States, it is starting to take off. Dr. Allan Mishra, an orthopedist at Stanford University Medical Center, has been a pioneer in its use in the United States. He first started using PRP in 2001. I spoke to Dr. Mishra tonight and he pointed out that healing in the tendons and cartilages tends to be poor because of limited blood supply. With PRP, "you're taking a component of your own blood, concentrating the wound-healing components and injecting those back into your body into an area where you are not able to heal very well." In brief, he adds, "you're trying to take advantage of your own body's ability to heal itself."
Traditional treatment of tendonitis has concentrated on reducing inflammation with non-steroidal anti-inflammatory medications (NSAID's), steroid injections, or rest. But the goal of PRP therapy is to promote healing rather than just decrease inflammation. Dr. Mishra estimates that he's treated between 100 and 200 patients, and that across the United States several thousand patients have been treated for orthopedic injuries. Over the past 12 months he's treated about 60 patients – mostly with elbow tendonitis (tennis elbow), knee tendonitis, and Achilles tendon repairs. With tennis elbow, for example, "you see improvement within two to four months." Dr. Mishra says that so far side-effects have mostly been limited to pain and swelling at the injection site. The cost is about $1,500 per treatment.
The use of platelet rich plasma is not specifically FDA approved for use in tendonitis or cartilage injuries. Dr. Mishra is the director of a large, multi-center study looking into the effectiveness and safety of PSP for treatment of damaged cartilage, tennis elbow and inflammation of the foot (plantar fasciitis). He estimates the study will be completed in one to two years.